Skip to main content

Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer

Current Oncology Reports volume 9, pages 469–471 (2007)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Rose PG, Mossbruger K, Fusco N, et al.: Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum-and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol 2003, 88:17–21.

    PubMed  Article  CAS  Google Scholar 

  2. du Bois A, Luck HJ, Pfisterer J, et al.: Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer—a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol 2001, 12:1115–1120.

    PubMed  Article  Google Scholar 

  3. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1–6.

    PubMed  Article  CAS  Google Scholar 

  4. Vasey PA, Jayson GC, Gordon A, et al.: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004, 96:1682–1691.

    PubMed  CAS  Article  Google Scholar 

  5. Jaaback K, Johnson N: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006, CD005340.

  6. Bookman MA: GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel and carboplatin vs combinations with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced-stage epithelial ovarian or primary peritoneal carcinoma [abstract]. Proc ASCO 2006, 24:5002.

    Google Scholar 

  7. Bolis G, Scarfone G, Giardina G, et al.: Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin-or carboplatin-sensitive ovarian cancer. Gynecol Oncol 2001, 81:3–9.

    PubMed  Article  CAS  Google Scholar 

  8. Parmar MK, Ledermann JA, Colombo N, et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099–2106.

    PubMed  Article  CAS  Google Scholar 

  9. Pfisterer J, Plante M, Vergote I, et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG [abstract]. Proc ASCO 2006, 24:5005.

    Google Scholar 

Download references

Authors
  1. Robert L. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Coleman, R.L. Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer. Curr Oncol Rep 9, 469–471 (2007). https://doi.org/10.1007/s11912-007-0065-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0065-5

Keywords

  • Ovarian Cancer
  • Paclitaxel
  • Gemcitabine
  • Carboplatin
  • Topotecan